low price cryptocurrency to invest 2021 Top People searches

Yingli shares: Yingli shares increased capital by 80 million yuan to its holding subsidiary. Yingli shares announced that the company and Shanghai Moqin Intelligent Technology Co., Ltd. increased capital to Nanchang Yingli Precision Manufacturing Co., Ltd., with a total capital increase of 80 million yuan, of which Yingli shares increased capital by 67 million yuan in cash and Shanghai Moqin increased capital by 13 million yuan in cash. After this capital increase, the registered capital of Nanchang Yingli will increase from 20 million yuan to 100 million yuan. After the capital increase is completed, Yingli shares hold 80% of the shares of Nanchang Yingli and Shanghai Moqin holds 20% of the shares. This capital increase does not constitute a connected transaction and does not need to be submitted to the company's shareholders' meeting for consideration.Shanghai Gold Exchange: the settlement price of NYAuTN12 contract in Shanghai New Zealand was 627.85 yuan/gram. On December 13th, Shanghai Gold Exchange issued a notice saying that NYAuTN12 contract in Shanghai New Zealand was settled on December 13th, 2024. The details of the settlement of the contract are as follows: the settlement price of NYAuTN12 contract in Shanghai New Zealand was 627.85 yuan/gram.Changshu Automobile Accessories: It is planned to invest 22.8 million yuan to set up a joint venture with Antonlin Investment Co., Ltd. Changshu Automobile Accessories announced that the company plans to set up a joint venture with Antonlin Investment Co., Ltd. in Wuhu City, Anhui Province, tentatively named Wuhu Antonlin Intelligent Cockpit System Co., Ltd., with an estimated total investment of 140 million yuan, including a registered capital of 57 million yuan. The company invested 22.8 million yuan, accounting for 40% of the total share capital of Antonglin in Wuhu; Antonglin Investment Co., Ltd. contributed 34.2 million yuan, accounting for 60% of the total share capital of Antonglin in Wuhu. The establishment of the new company will expand the company's industrial layout, improve the company's comprehensive competitive strength and realize the company's strategic plan for sustainable development.

Ha Sanlian: Four kinds of drugs are planned to win the bid for national centralized procurement. Ha Sanlian announced that the company and its wholly-owned subsidiary Lanxi Pharmaceutical participated in the tenth batch of national centralized procurement of drugs organized by the state. The company's esmolol hydrochloride injection, pentoxifylline injection, potassium chloride injection, and tandospirone citrate tablets of Lanxi Pharmaceutical intend to win the bid for this centralized procurement. If the subsequent purchase contract is signed and implemented, it will help to expand the sales of related products and improve the market share and brand influence. The prices of the above-mentioned drugs are respectively 1.34 yuan for esmolol hydrochloride injection, 0.59 yuan for pentoxifylline injection, 0.16 yuan for potassium chloride injection and 6.56 yuan for tandospirone citrate tablets.Guoxin Technology: Serialized chip products have been launched in the field of automotive electronic MCU. Guoxin Technology said in an investigation that the company has launched serialized chip products in the field of automotive electronic MCU in recent years, which has been welcomed by the market; Through the implementation of the strategy of "standing on the ground" and "overwhelming", this year, the company's automobile electronic MCU chip business has formed certain advantages, and obvious progress has been made in loading application and shipment volume. The product price is relatively stable, the fluctuation range is small, and the gross profit margin of the product remains relatively stable. In 2024, the company's BMS main control chip CCFC2007PT, high-end domain control chip CCFC3007PT, airbag ignition drive chip CCL1600B, etc. have all been used for loading/installing, and several manufacturers are developing at designated locations based on the above chips. In the future, with the increase of fixed-point mass production projects, shipments are expected to continue to grow.Puli Pharmaceutical Co., Ltd.: It won the bid for the tenth batch of national centralized drug procurement. According to Puli Pharmaceutical, on December 12, Puli Pharmaceutical's meglumine gadolinium tetate injection (trade name: Puli Yingxian) and Posaconazole injection (trade name: Puli Posa) both won the bid for the tenth batch of national centralized drug procurement.

Liao Min held video talks with the heads of sovereign credit rating teams of international credit rating companies. Recently, Vice Minister of Finance Liao Min held video talks with Mary Duron, global head of Moody's Sovereignty and Local Government Risk Department, and Roberto Xifeng-Arevalo, global head of Standard & Poor's Sovereignty Rating Team, respectively, to introduce the latest incremental policies of the China government, and exchanged views with each other on issues such as government debt management, fiscal sustainability, fiscal policy supporting the high-quality development of the real economy, and fiscal and taxation system reform. Both Moody's and Standard & Poor's said that the introduction of the Ministry of Finance was comprehensive and frank, which was very helpful for them to deepen their understanding of the macro policies of the China government, and they looked forward to more exchanges between the two sides. (Ministry of Finance)Hite Bio: Two drugs are planned to be selected for national centralized drug procurement. Hite Bio announced that the company participated in the tenth batch of national centralized drug procurement. According to the selected results released by the joint procurement, roxatidine acetate hydrochloride and pentoxifylline injection for injection of the company are selected for this centralized procurement. These two drugs are suitable for the treatment of upper gastrointestinal bleeding and peripheral arterial diseases respectively. The procurement cycle is from the date of implementation of the selected results to December 31, 2027, during which medical institutions will give priority to the use of selected drugs. The company obtained the Drug Registration Certificate of the above drugs in 2024, but it has not generated sales revenue this year. This election will help to enhance the brand influence of the company and have a positive impact on the company's development.Zhonglu Co., Ltd.: The total amount of taxes and late fees paid is 15,430,100 yuan. Zhonglu Co., Ltd. announced that the company, as a limited partner of Zhonglu Advantage, received its cash asset distribution according to the resolution of Zhonglu Advantage Partner Meeting. In view of the above-mentioned asset allocation matters, the company strictly abides by the relevant regulations and adopts the principle of "tax after distribution". As required, it has declared and paid enterprise income tax of 11,770,500 yuan and late payment fee of 3,659,500 yuan, totaling 15,430,100 yuan. The late payment fee paid by the company will be included in the current profit and loss in 2024, which is expected to affect the company's net profit attributable to shareholders of listed companies in 2024 by about 3,659,500 yuan.